Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials

Publication date: Available online 17 January 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Carlos Iribarren, Kenneth J. Rothman, Mary S. Bradley, Gillis Carrigan, Mark D. Eisner, Hubert Chen

Teaser

Capsule summary: Among patients who participated in randomized clinical trials of omalizumab, no substantial overall increase in the risk of cardiovascular events was observed in the treatment arms compared with placebo. <<29/35 words>>


http://ift.tt/2jKgz20